Altamira Therapeutics Ltd. · OTC:CYTOF

Altamira Therapeutics — Auris Medical Holding — Investor Presentation (February 2015)

31 slides from Altamira Therapeutics's investor presentation, Feb 11, 2015

  1. Slide 1: Company Presentation February 2015

    Slide 1: Company Presentation February 2015

    Company Presentation February 2015 0

  2. Slide 2: Forward Looking Statements / Safe Harbor

    Slide 2: Forward Looking Statements / Safe Harbor

    Forward Looking Statements / Safe Harbor [] This presentation and the accompanying oral commentary contain "forward -looking" statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation and the accompanying oral

  3. Slide 3: Corporate Overview

    Slide 3: Corporate Overview

    Corporate Overview [] Auris Medical is a clinical late stage company dedicated to developing inner ear therapeutics [] Headquartered in Zug/Basel, Switzerland [] Founded in 2003 [] IPO completed in August 2014 [] Nasdaq Global Market: EARS [] 28.9M shares [] Market cap $152M (*) (*) As at February 6

  4. Slide 4: Investment Highlights

    Slide 4: Investment Highlights

    Investment Highlights 1 Tinnitus and hearing loss represent a large unmet medical need 2 Injectable ear therapeutics to change otology as profoundly as injectable eye therapeutics changed ophthalmology Clinical Proof of Concept demonstrated with 2 late stage 3 product candidates 4 High margin produc

  5. Slide 5: Leadership Team

    Slide 5: Leadership Team

    Leadership Team Thomas Meyer, PhD Founder, Chairman and CEO [] Former CEO and BoD member of Disetronic (diabetes care) [] Instrumental in Disetronic's IPO and managing 20% sales CAGR over many years [] 3 bn CHF market cap Bettina Stubinski, MD, MBA Chief Medical Officer [] Former Global Head Clinica

  6. Slide 6: Development Pipeline

    Slide 6: Development Pipeline

    Development Pipeline Product Indication Preclin. Phase 1 Phase 2 Phase 3 Next Key Milestones(1) ----------- ----------------------------- -------- ------- ------- ------- ----------------------------- Data TACTT2 Acute inner ear tinnitus Early 2016 AM-101 Data TACTT3 ----------------------------- --

  7. Slide 7: Inner Ear Disorders -- Great Unmet Medical Need

    Slide 7: Inner Ear Disorders -- Great Unmet Medical Need

    Inner Ear Disorders -- Great Unmet Medical Need Tinnitus [] About 16M patients in the US have tinnitus symptoms severe enough to seek medical attention [] About 2M patients cannot function on a normal day-to-day basis [] Tinnitus is now the #1 service related disability for all veterans [] Annual se

  8. Slide 8: Some Patient Testimonials

    Slide 8: Some Patient Testimonials

    Some Patient Testimonials "I have been suffering with tinnitus for 4 months. I will admit my life has turned for the worse since this occurred. Lost interest in all things and really don't go out much anymore ...You don't know how I would like to get back to the way I was." "You really need to hurry

  9. Slide 9: Intratympanic Drug Delivery

    Slide 9: Intratympanic Drug Delivery

    Intratympanic Drug Delivery [GRAPHIC OMITTED] [] Short office based ENT procedure [] Biocompatible, biodegradable sodium hyaluronate gel [] 0.25 mL injected from pre-filled syringe under local anesthesia [] 20-30' resting period for diffusion across round window membrane [] Site specific delivery wi

  10. Slide 10: AM-101 for the Treatment of Acute Inner Ear Tinnitus

    Slide 10: AM-101 for the Treatment of Acute Inner Ear Tinnitus

    AM-101 for the Treatment of Acute Inner Ear Tinnitus

  11. Slide 11: AM-101 for Acute Inner Ear Tinnitus

    Slide 11: AM-101 for Acute Inner Ear Tinnitus

    AM-101 for Acute Inner Ear Tinnitus Significant [] Similar to pain, tinnitus is an unpleasant, unwanted sensation Unmet Medical [] Significant impact on sleep, ability to concentrate or relax Need [] Substantial emotional distress and reduced quality of life Attractive [] Treat tinnitus within first

  12. Slide 12: AM-101 Mechanism of Action

    Slide 12: AM-101 Mechanism of Action

    AM-101 Mechanism of Action [] Cochlear NMDA receptors -- Regulate surface expression of AMPA receptors -- Neurotrophic role post acute insult [] Not involved in normal hearing [] Acute injury leads to NMDA mediated glutamate excitotoxicity -- Pathologic Ca(2+) influx into postsynapse -- Similar e. g

  13. Slide 13: AM-101 Clinical Development

    Slide 13: AM-101 Clinical Development

    AM-101 Clinical Development Tinnitus Etiology AM-101 ------------------------ ------------------------------- ------------------------- Traumatic insult Otitis media Idiopathic (mg/mL) ------- ------------------------ ------------------------------- ------------------------- ------------- 1 x Phase

  14. Slide 14: Proof of Concept in Phase 2 (TACTT0)

    Slide 14: Proof of Concept in Phase 2 (TACTT0)

    Proof of Concept in Phase 2 (TACTT0) Tinnitus Loudness (Unilaterals) 48% reduction from baseline Placebo AM-101 0.27 mg/mL AM-101 0.81 mg/mL [GRAPHIC OMITTED] Baseline (on 0-100 scale): 50-55 points Clinically relevant change = 20 points 56% responders high dose vs. 23% placebo group N=78 (only unil

  15. Slide 15: Proof of Concept in Phase 2 (Cont'd)

    Slide 15: Proof of Concept in Phase 2 (Cont'd)

    Proof of Concept in Phase 2 (Cont'd) Key Outcomes Day 90 Outcome variable Placebo AM-101 0.27 AM-101 0.81 g/mL g/mL ANCOVA Least Square Mean Change from Baseline []Tinnitus loudness, 0- 1.4 16.0 24.1 100 pts. 0.0308* 0.0005*** ------------ ------------------ ---------------- []Tinnitus annoyance, 10

  16. Slide 16: AM-101 Phase 3 Program -- Pivotal Studies

    Slide 16: AM-101 Phase 3 Program -- Pivotal Studies

    AM-101 Phase 3 Program -- Pivotal Studies TACTT2 TACTT3 Region/countries USA, Canada, CZ 8 European countries Tinnitus following acute traumatic cochlear insults or otitis media Population (3 months from onset) # Patients 330 300 # Sites ~60 ~60 Treatment AM-101 0.87 mg/mL or placebo (ratio 3:2), 3

  17. Slide 17: AM-101 Phase 3 Program -- Further Studies

    Slide 17: AM-101 Phase 3 Program -- Further Studies

    AM-101 Phase 3 Program -- Further Studies [] Post-Acute Stage [] Multiple regression analysis of TACTT0 suggests efficacy beyond 3-month acute stage [] Exploring extension of therapeutic time window up to 12 months in a second stratum in TACTT3 (300 patients) [] Interim analysis for futility at enro

  18. Slide 18: AM-101 Market Potential

    Slide 18: AM-101 Market Potential

    AM-101 Market Potential Primary Market Research [] 53 US ENT doctors surveyed (1) -- 41 general ENTs -- 12 otologists [] See an average of 43.5 tinnitus patients in an average month [] 37.7% of their tinnitus patients seek treatment during the acute stage (up to 3 months from onset) [] 73.6% of resp

  19. Slide 19: AM-111 for the Treatment of Acute Inner Ear Hearing Loss

    Slide 19: AM-111 for the Treatment of Acute Inner Ear Hearing Loss

    AM-111 for the Treatment of Acute Inner Ear Hearing Loss (@ Auris Medical rrapies

  20. Slide 20: AM-111 for Acute Inner Ear Hearing Loss

    Slide 20: AM-111 for Acute Inner Ear Hearing Loss

    AM-111 for Acute Inner Ear Hearing Loss Significant [] Significant impact on cognitive and auditory function Unmet Medical [] Substantially reduced quality of life Need [] Hearing aids cannot replace functional cochlea Attractive [] Preserve cochlear function before hearing loss becomes irreversible

  21. Slide 21: AM-111's Mechanism of Action

    Slide 21: AM-111's Mechanism of Action

    AM-111's Mechanism of Action [] C-jun N-terminal Kinase (JNK) stress kinase involved in various cochlear insults [] Plays key role in apoptosis and inflammation [] D-JNKI-1 is a 31 amino acid intracellular peptide inhibiting JNK mediated transcription [] Therapeutic time window to preserve sensorine

  22. Slide 22: AM-111 Clinical Development

    Slide 22: AM-111 Clinical Development

    AM-111 Clinical Development [] Two trials completed, including one phase 2 RCT [] Sudden deafness (90%) and acute acoustic trauma (10%) patients [] Favorable safety profile with no systemic side effects [] Proof of concept in severe to profound hearing loss patients -- Hearing loss of 60 dB or more

  23. Slide 23: Proof of Concept in Phase 2 Key Outcomes

    Slide 23: Proof of Concept in Phase 2 Key Outcomes

    Proof of Concept in Phase 2 Key Outcomes AM-111 AM-111 Outcome variable Placebo 0.4 mg/mL 2.0 mg/mL ANCOVA Mean Change to Day 7 (Primary Endpoint) [] Hearing threshold (LS 17.9 29.9 22.7 mean, dB) 0.0174* 0.3186 [] Speech discrimination 9.1 27.4 23.2 (LS mean, %) 0.0186* 0.0609 Frequency at Day 90 [

  24. Slide 24: AM-111 Phase 3 Program

    Slide 24: AM-111 Phase 3 Program

    AM-111 Phase 3 Program HEALOS US trial Region Europe, Asia US Population Severe to profound sudden deafness, ASNHL within 72 hours from onset (subtype tbd) # Patients 255 tbd # Sites 70-80 tbd Treatment 1 x AM-111 0.4 mg/mL, 0.8 mg/mL or tbd placebo (ratio 1:1:1) Primary endpoint []Hearing threshold

  25. Slide 25: AM-111 Market Potential

    Slide 25: AM-111 Market Potential

    AM-111 Market Potential Primary Market Research [] 53 US ENT doctors surveyed (1) -- 41 general ENTs -- 12 otologists [] See an average of 11.2 patients with ISSNHL and 6.3 patients with AAT in an average month [] 39.9% seek treatment within first 3 days and 43.3% have severe to profound hearing los

  26. Slide 26: IP, Financial Position & Commercialization Strategy

    Slide 26: IP, Financial Position & Commercialization Strategy

    IP, Financial Position & Commercialization Strategy

  27. Slide 27: Strong Intellectual Property Portfolio

    Slide 27: Strong Intellectual Property Portfolio

    Strong Intellectual Property Portfolio 1 AM-101 [] Use patents issued in 40 countries -- 2024 to 2028 (US) [] Controlled substance in major markets (schedule III in US) [] Esketamine currently not marketed in US 2 AM-111 [] Substance of matter patents issued/allowed in 54 countries -- 2020 to 2027 (

  28. Slide 28: Market Strategy

    Slide 28: Market Strategy

    Market Strategy Commercialization [] Retain full rights in US and key EU markets to commercialize AM-101 and AM-111 [] Targeting about 5,000 otologists, neurotologists and general ENTs in US -- Specialist sales force to call on ENTs -- 40-50 reps in US -- Smaller number needed than in ophthalmology

  29. Slide 29: Financial Overview

    Slide 29: Financial Overview

    Financial Overview Key figures (CHF) Nine months ended Nine months ended Sep 30, 2014 Sep 30, 2013 Research and development -13,036,450 -10,327,366 General and administrative -3,552,021 -1,010,096 Operating loss -16,588,471 -11,337,462 Net loss for the period attributable to owners of the Company -1

  30. Slide 30: Investment Highlights

    Slide 30: Investment Highlights

    Investment Highlights 1 Tinnitus and hearing loss represent a large unmet medical need 2 Injectable ear therapeutics to change otology as profoundly as injectable eye therapeutics changed ophthalmology Clinical Proof of Concept demonstrated with 2 late stage 3 product candidates 4 High margin produc

  31. Slide 31: Take care of your ears!

    Slide 31: Take care of your ears!

    Take care of your ears!

Source: SEC EDGAR · 6-K filed Feb 11, 2015

More decks from Altamira Therapeutics Ltd.

All 7 Altamira Therapeutics decks